Ascendis Pharma (ASND) announced that it has initiated a Phase 3 clinical trial, called heiGHt, evaluating lead product candidate TransCon Growth Hormone for the treatment of children with growth hormone deficiency (GHD). The trial design mirrors its successful Phase 2 study. The study will enroll ~150 treatment-naive children with GHD. The primary endpoint is height velocity after 12 months of treatment. The study is expected to be completed in December 2018.